Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis

Journal of Immunology

Volumn 180, Issue 4, 2008, Pages 2132-2139

  Aricha, Revital ^a   Feferman, Tali ^a   Fuchs, Sara ^a   Souroujon, Miriam C ^a,b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b OPEN UNIVERSITY OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD28 ANTIGEN; CD3 ANTIBODY; CHOLINERGIC RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HUMORAL ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; CD24 ANTIGEN; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, RAT; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL LINE; CELL POPULATION; CELL PROLIFERATION; CELL STIMULATION; CELL THERAPY; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; EX VIVO STUDY; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; MYASTHENIA GRAVIS; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T LYMPHOCYTE; ANIMAL; BIOSYNTHESIS; BLOOD; CELL DIFFERENTIATION; CYTOLOGY; DRUG ANTAGONISM; IMMUNOLOGY; LEWIS RAT; LYMPHOCYTOPENIA; METABOLISM; PATHOLOGY; TH1 CELL; TH2 CELL; TRANSPLANTATION;

ANIMALS; ANTIGENS, CD24; CELL DIFFERENTIATION; CYTOKINES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOPENIA; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RATS; RATS, INBRED LEW; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS;

EID: 42149145285     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.4.2132     Document Type: Article

References (46)

1. Im, S. H., D. Barchan, P. K. Maiti, L. Raveh, M. C. Souroujon, and S. Fuchs. 2001. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J. 15: 2140-2148.
2. Karachunski, P. I., N. S. Ostlie, C. Monfardini, and B. M. Conti-Fine. 2000. Absence of IFN-γ or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J. Immunol. 164: 5236-5244.
3. Ostlie, N. S., P. I. Karachunski, W. Wang, C. Monfardini, M. Kronenberg, and B. M. Conti-Fine. 2001. Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis. J. Immunol. 166: 4853-4862.
4. Becker, C., S. Stoll, T. Bopp, E. Schmitt, and H. Jonuleit. 2006. Regulatory T cells: present facts and future hopes. Med. Microbiol. Immunol. 195: 113-124.
5. Miyara, M., and S. Sakaguchi. 2007. Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med. 13: 108-116.
6. Hori, S., and S. Sakaguchi. 2004. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect. 6: 745-751.
7. + regulatory T cells. Nat. Immunol. 4: 330-336.
8. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
9. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212: 8-27.
10. Wan, Y. Y., and R. A. Flavell. 2007. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445: 766-770.
11. Fattorossi, A., A. Battaglia, A. Buzzonetti, F. Ciaraffa, G. Scambia, and A. Evoli. 2005. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 116: 134-141.
12. + T cells in myasthenia gravis patients with stability and thymectomy. Clin. Immunol. 112: 284-289.
13. Luther, C., S. Poeschel, M. Varga, A. Melms, and E. Tolosa. 2005. Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma. J. Neuroimmunol. 164: 124-128.
14. + T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105: 735-741.
15. Wang, W., M. Milani, N. Ostlie, D. Okita, R. K. Agarwal, R. Caspi, and B. M. Conti-Fine. 2007. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-γ are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J. Immunol. 178: 7072-7080.
16. Shi, F. D., H. Li, H. Wang, X. Bai, P. H. van der Meide, H. Link, and H. G. Ljunggren. 1999. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. J. Immunol. 162: 5757-5763.
17. + regulatory T cells. J. Immunol. 177: 5296-5306.
18. + T regulatory cells in the prevention of autoimmune myasthenia. J. Immunol. 175: 7898-7904.
19. Ben-David, H., B. V. Aruna, R. Seger, M. Sela, and E. Mozes. 2006. A 50-kDa ERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses. Proc. Natl. Acad. Sci. USA 103: 18232-18237.
20. Aricha, R., T. Feferman, M. C. Souroujon, and S. Fuchs. 2006. Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. FASEB J. 20: 374-376.
21. Aharonov, A., R. Tarrab-Hazdai, I. Silman, and S. Fuchs. 1977. Immunochemical studies on acetylcholine receptor from Torpedo californica. Immunochemistry 14: 129-137.
22. Lennon, V. A., E. H. Lambert, K. R. Leiby, T. B. Okarma, and S. Talib. 1991. Recombinant human acetylcholine receptor α-subunit induces chronic experimental autoimmune myasthenia gravis. J. Immunol. 146: 2245-2248.
23. Maiti, P. K., T. Feferman, S. H. Im, M. C. Souroujon, and S. Fuchs. 2004. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J. Neuroimmunol. 152: 112-120.
24. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2: 389-400.
25. + immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol. 16: 81-88.
26. + T cell subset committed in vivo to suppress antigen-specific T cell responses without additional stimulation. Eur. J. Immunol. 34: 3016-3027.
27. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22: 531-562.
28. + T cell levels in NOD mice. Proc. Natl. Acad. Sci. USA 99: 12287-12292.
29. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238.
30. + T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 104: 453-461.
31. high regulatory T cells. Blood 104: 895-903.
32. Tang, Q., K. J. Henriksen, M. Bi, E. B. Finger, G. Szot, J. Ye, E. L. Masteller, H. McDevitt, M. Bonyhadi, and J. A. Bluestone. 2004. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199: 1455-1465.
33. + T lymphocyte by adenovirus-mediated gene transfer of CTLA4Ig fusion protein in experimental autoimmune myocarditis. Autoimmunity 39: 289-298.
34. + regulatory T cells from human peripheral blood. J. Immunol. 166: 7282-7289.
35. + regulatory T cells with indirect allospecificity: potential reagents to promote donor-specific transplantation tolerance. Transplantation 82: 1738-1743.
36. Loser, K., W. Hansen, J. Apelt, S. Balkow, J. Buer, and S. Beissert. 2005. In vitro-generated regulatory T cells induced by Foxp3-retrovirus infection control murine contact allergy and systemic autoimmunity. Gene Ther. 12: 1294-1304.
37. - cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J. Immunol. 172: 5213-5221.
38. + regulatory T cells suppress Th1 mediated experimental colitis. Gut 55: 671-680.
39. + regulatory T cells and for expansion of these cells. J. Immunol. 178: 2018-2027.
40. Horwitz, D. A., S. G. Zheng, J. D. Gray, J. H. Wang, K. Ohtsuka, and S. Yamagiwa. 2004. Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin. Immunol. 16: 135-143.
41. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99: 3493-3499.
42. + regulatory T cells suppress differentiation and functions of Th1 and Th2 cells, Leishmania major infection, and colitis in mice. J. Immunol. 170: 394-399.
43. von Boehmer, H. 2005. Mechanisms of suppression by suppressor T cells. Nat. Immunol. 6: 338-344.
44. Feng, N. H., H. F. Wu, J. Wu, W. Zhang, Y. G. Sui, H. G. He, C. L. Zhang, and J. S. Zheng. 2004. Transplantation tolerance mediated by regulatory T cells in mice. Chin. Med. J. 117: 1184-1189.
45. + cells in the recipient. Int. Immunol. 18: 279-289.
46. Bluestone, J. A. 2005. Regulatory T-cell therapy: is it ready for the clinic? Nat. Rev. Immunol. 5: 343-349.